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Abstract
Background Adjuvant chemoradiotherapy (CRT) is the
standard treatment in Western countries for gastric cancer
patients submitted to curative resection. However, the role
of adjuvant CRT in gastric cancer treated with D2 lym-
phadenectomy has not been well defined.
Methods We conducted a retrospective study in patients
with stage II to IV gastric adenocarcinoma with no distant
metastases, who underwent curative resection with D2
lymphadenectomy between January 2002 and December
2007. The present study compared the 3-year overall sur-
vival of two treatments (adjuvant CRT according to the
INT 0116 trial versus resection alone). Survival curves
were estimated by the Kaplan–Meier method and com-
pared with a log-rank test. Multivariate analysis of prog-
nostic factors was performed by the Cox proportional
hazards model.
Results A total of 185 patients were included, 104
patients (56 %) received adjuvant CRT and 81 received
resection alone. The 3-year overall survival was 64.4 % in
the CRT group and 61.7 % in the resection-alone group
(p: 0.415). However, according to the Cox proportional
hazards model, adjuvant CRT was a prognostic factor for
3-year overall survival (hazard ratio [HR] 0.46, 95 %
confidence interval [CI] 0.26–0.82, p: 0.008).
Conclusions In the present study, adjuvant CRT was
associated with a lower risk of death over a 3-year period in
gastric cancer patients treated with D2 lymphadenectomy.
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Introduction
Gastric cancer is a malignant neoplasm with the fourth-
highest incidence worldwide, represents the second-great-
est cause of cancer-related deaths, and frequently affects
the populations of Latin America, Eastern Europe, China,
and Japan [1, 2].
Gastric cancer that is limited to the stomach and to
regional lymph nodes is potentially curable by surgical
resection. However, about 20–40 % of all patients
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submitted to resection with no further treatment will suffer
a relapse of the disease within 2 years [3, 4]. Once a
relapse occurs, no curative treatment is available and the
median survival is about 6 months [3].
In view of these unfavorable outcomes of recurrent
gastric cancer, adjuvant treatments have been tested during
the past decade. In 2001, based on the results of the INT
0116 trial, adjuvant chemoradiotherapy with 5-fluorouracil
started to be widely accepted in Western countries by
demonstrating a significant benefit in overall survival [5].
However, the results of the trial were contested because
only 10 % of the population studied had been submitted to
D2 lymphadenectomy, which is considered to reduce the
risk of locoregional recurrence and the risk of death related
to gastric cancer [5, 6].
The presence of residual disease in nonresected lymph
nodes, which can be measured with a quantitative estimator
denoted as the Maruyama index, is an independent prog-
nostic factor in patients with gastric cancer [7–9]. The
addition of radiotherapy to adjuvant therapy can be a useful
strategy in patients submitted to more limited dissections,
with a higher risk of microscopic locoregional disease. In
patients with more extensive dissections, radiotherapy may
not be of additional benefit in terms of survival and may
actually have a deleterious effect by increasing the toxicity
of treatment [5, 10–12].
Recent data support the hypothesis that patients with
gastric cancer benefit from adjuvant chemotherapy [13],
but there is still no agreement about the therapeutic regi-
men to be employed. Perioperative chemotherapy or
adjuvant chemotherapy alone has proven to be promising
in clinical trials with predominantly D2 lymphadenectomy
dissection [14–17].
The objective of the present study was to assess the
influence of adjuvant chemoradiotherapy on the overall
survival of patients with gastric cancer submitted to D2
lymphadenectomy.
Patients and methods
This was a retrospective cohort study conducted in patients
with a histological diagnosis of stage II to IV gastric or
esophagogastric junction (EGJ) adenocarcinoma, with no
distant metastases, according to the classification of the
American Joint Committee on Cancer 6th edition. These
patients were submitted to curative resection and D2
lymphadenectomy at the Barretos Cancer Hospital
(Barretos, Sa˜o Paulo, Brazil) between January 2002 and
December 2007.
Surgical treatment consisted of gastrectomy with free
margins (R0 resection) and D2 lymphadenectomy, without
splenectomy or caudal pancreatectomy. The procedure
was performed by a single team of oncology surgeons
with training in surgery of the digestive system. The
indication for chemoradiotherapy or for resection alone
was based on the clinical judgment of the oncology team,
which consisted of surgical, medical, and radiation
oncologists.
Adjuvant therapy consisted of five cycles of intrave-
nous 5-fluorouracil and leucovorin (425 and 20 mg/m2,
respectively, daily) for 5 days, every 28 days, concomi-
tant with radiotherapy in cycles two and three, when the
dose of 5-fluorouracil was reduced to 400 mg/m2,
according to the INT 0116 trial [5]. The total radiotherapy
dose was 45 Gy in 25 fractions over 5 days of the week
and was applied to the tumor bed; areas of anastomosis;
and perigastric, celiac, para-aortic, splenic, hepatoduode-
nal; and pancreatoduodenal lymph nodes. In tumors of the
EGJ and of the proximal portions of the stomach, the field
was proximally expanded by 3–5 cm to include the distal
esophagus area and part of the left hemidiaphragm, as
well as regions of paracardiac and paraesophageal lymph
nodes. Anteroposterior (AP) and posteroanterior (PA)
fields were used in the conventional technique, with a
6-MV linear accelerator or cobalt unit. The cardiac area
was protected with blocks and at least 2/3 of one kidney
was spared from irradiation.
After the end of treatment, the patients were followed up
by anamnesis, physical examination, laboratory tests
(blood count, hepatic function and renal function) and a
chest radiograph every 3 months during the first 2 years,
every 4 months during the third year, and every 6 months
starting in the fourth year. Patients were also given an
abdominal ultrasound every 4 months during the first
2 years and every 6 months starting in the third year.
Computed tomography, nuclear magnetic resonance, and
upper digestive endoscopy were performed upon clinical
indication.
Recurrence was diagnosed based on clinical examina-
tion findings and on the complementary tests performed
according to the above schedule, with a description of all
sites diagnosed during the follow up. Recurrence at the
surgical site, in the anastomosis, and in the regional lymph
nodes was considered to be locoregional. Peritoneal
implants or ascites with no other evident cause were con-
sidered to be signs of peritoneal recurrence. Systemic
recurrence was considered if distant metastases appeared,
including retroperitoneal lymph nodes. Patients with
recurrences were evaluated for palliative chemotherapy.
The study compared the 3-year overall survival, as well
as the rates and sites of recurrence, in the group of patients
submitted to gastrectomy and D2 lymphadenectomy alone
(GL) with these parameters in the group of patients sub-
mitted to adjuvant chemoradiotherapy (GL ? CRT).
Finally, the prognostic factors for survival were identified.
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The categorical variables in the two groups were com-
pared by the v2 test and the continuous variables were
compared by the Mann–Whitney test. Overall survival was
defined as the time, in months, elapsed from the date of
surgery to the date of death from any cause. The 3-year
overall survival was estimated by the Kaplan–Meier
method, and the survival curves were compared by the log-
rank test. The patients lost to follow up were censored on
the date of last contact with the center. Surviving patients
were censored within 36 months for the analysis of overall
survival. Prognostic factors were assessed by multivariate
analysis using the Cox proportional hazards model, and
p values of less than 0.05 were considered to indicate
statistical significance. The analyses were performed with
SPSS 13.0 software (SPSS, Chicago, IL, USA).
The study was approved by the ethics committee of the
participating center.
Results
Of the 185 patients selected, 113 (61 %) were males. The
median age was 61 years. The median follow up was
30.8 months. Gastric tumors represented 85 % of the cases,
and the remaining tumors were those of the EGJ. All
patients underwent R0 resection and D2 lymphadenec-
tomy. Nine patients (4.6 %) died during the postoperative
period and were not included in the analysis.
A total of 104 (56 %) patients were submitted to adju-
vant chemoradiotherapy, and 81 were treated with resec-
tion alone. GL ? CRT patients were younger and
presented more advanced nodal status and TNM stage than
GL patients. The characteristics of the groups are listed in
Table 1. The rates and sites of recurrence and the fre-
quency of locoregional, peritoneal, and systemic recur-
rence are listed in Table 2.
During the follow-up period, 68 deaths occurred, 37 in
GL ? CRT patients and 31 in GL patients. The 3-year
overall survival rate was 63.4 %. Median survival was not
reached. The 3-year overall survival rate was 64.4 % for
GL ? CRT and 61.7 % for GL (p: 0.415) (Table 2; Fig. 1).
The Cox proportional hazards model adjusted for age,
gender, depth of invasion, nodal status, TNM stage, tumor
location, Laure´n histology, and adjuvant treatment revealed
that only TNM stage and adjuvant treatment had influence
on overall survival (Table 3). The patients treated with
chemoradiotherapy had a 54 % reduction of the risk of
death within 3 years (hazard ratio [HR] 0.46 95 % confi-
dence interval [CI] 0.26–0.82; p: 0.008). The HR differed
according to stage of disease (Table 4). Patients with no
information about Laure´n histology (11 patients) were
excluded from the multivariate analysis. Only one treat-
ment-related death occurred among GL ? CRT patients.
The administration of palliative chemotherapy was also
similar for both groups, i.e., 16.5 % in GL ? CRT and
11.3 % in GL (p: 0.313).
Table 1 Characteristics of the patients
Characteristics GL ? CRT GL p
No. (%) No. (%)
Total 104 (100) 81 (100)
Male sex 61 (59) 52 (64) 0.443
Median age, years (range) 59 (30–81) 68 (27–88) 0.005
Tumor location
Stomach 88 (85) 68 (84) 0.455
EGJ 16 (15) 13 (16)
Surgery performed
Total gastrectomy 56 (53) 32 (40) 0.244
Subtotal gastrectomy 41 (40) 39 (48)
Esophagogastrectomy 4 (4) 5 (6)
Resection of the gastric stump 3 (3) 5 (6)
Median number of dissected
lymph nodes (range)
22 (12–52) 17 (12–66) 0.716
Laure´n histology
Intestinal-type 60 (58) 48 (66) 0.391
Diffuse-type 38 (37) 20 (27)
Mixed-type 5 (5) 4 (6)
Undifferentiated 0 (0) 1 (1)
Tumor depth
T1 0 (0) 1 (1) 0.678
T2 14 (13) 9 (11)
T3 83 (80) 65 (80)
T4 7 (7) 6 (8)
Nodal status
N0 21 (20) 30 (37) 0.005
N1 44 (42) 38 (47)
N2 29 (28) 11 (13)
N3 10 (10) 2 (3)
TNM Stage
II 24 (23) 39 (48) 0.004
IIIA 46 (44) 26 (32)
IIIB 21 (20) 8 (10)
IV M0 13 (13) 8 (10)
EGJ esophagogastric junction, CRT chemoradiotherapy, GL gastrec-
tomy and D2 lymphadenectomy alone
Table 2 Overall survival and recurrence rates
Variable GL ? CRT GL p
3-Year overall survival (%) 64.4 61.7 0.415
Median follow up (months) 31.61 27.37 0.412
Locoregional recurrence (%) 8.9 3.7 0.159
Peritoneal recurrence (%) 13.9 6.2 0.092
Systemic recurrence (%) 17.8 16 0.752
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Discussion
The indication of adjuvant chemoradiotherapy for patients
submitted to curative gastrectomy and D2 lymphadenec-
tomy has been debated over the past few years. A retro-
spective study involving Eastern patients exclusively
operated on with D2 lymphadenectomy showed that adju-
vant treatment with combined therapy reduced the risks of
recurrence and death by 20 % [18]. The ARTIST [17] and
CLASSIC [16] trials recently raised the question of the
benefit of adjuvant chemoradiotherapy and chemotherapy
in Eastern patients submitted to D2 lymphadenectomy. On
the other hand, there are no studies that have evaluated the
effect of adjuvant chemoradiotherapy according to the
pivotal INT 0116 trial in a Western population who have
undergone D2 lymphadenectomy exclusively.
In the present study, the patients were evaluated for
eligibility for adjuvant treatment after surgery and there
was the possibility that postoperative complications (i.e.,
poor performance status, slow postoperative recovery, poor
nutritional status) influenced the decision of the choice of
adjuvant therapy. The limitations of this study could
explain the heterogeneity of the groups in relation to age,
TNM, and node stages, but the use of the regression model
adjusted for well-recognized prognostic factors aimed to
minimize the influence of these factors on the prognostic
value of adjuvant therapy.
Based on the analysis by the regression model with a
meaningful hazard ratio (HR), it was suggested that che-
moradiotherapy was associated with a lower risk of death
within 3 years, with a reduction of 54 %. There was a
different benefit derived from adjuvant therapy according
to disease stage (Table 4). Patients with stage IV disease
with no distant metastases derived the greater benefit from
the combined modality therapy, contributing to the
hypothesis that patients with more advanced nodal disease
could benefit from more intensive local therapy. It is pos-





















Fig. 1 Kaplan–Meier estimation of overall survival








B60 years 78 – – –
[60 years 96 1.37 0.78–2.42 0.267
Gender
Male 102 – – –
Female 72 1.00 0.60–1.66 0.976
Depth of invasion
Serosa-negative 23 – – –
Serosa-positive 151 1.21 0.34–4.24 0.759
Nodal status
Node-negative 45 – – –
Node-positive 129 1.49 0.31–6.98 0.610
TNM stage
II 57 – – –
IIIA 68 1.69 0.38–7.39 0.484
IIIB 29 4.05 0.79–20.57 0.091
IV M0 20 5.50 1.08–27.93 0.040
Location
Stomach 147 – – –
EGJ 27 1.76 0.90–3.44 0.094
Laure´n histology
Intestinal-type 107 – – –
Diffuse-type 59 1.29 0.75–2.23 0.354
Mixed-type 8 0.73 0.21–2.44 0.612
Adjuvant therapy
Resection alone 72 – – –
Chemoradiotherapy 102 0.46 0.26–0.82 0.008
a A total of 174 patients and 66 events (deaths) were considered in
the multivariate analysis
Table 4 Estimation of effect of adjuvant CRT on 3-year overall
survival stratified by TNM stage
Stage II Stage III Stage IV M0
n 63 101 21a
HR 0.53 0.70 0.25
95 % CI 0.14–1.96 0.38–1.31 0.08–0.78
a A total of 20 patients with stage IV M0 were considered in the
analysis, because one patient was censored before the first event
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patients affected the conclusions in relation to the whole
population. It is also important to emphasize that such a
model-based analysis imposes limitations on conclusions
about reduction of the risk of events when compared with
design-based analysis, which is usually performed in ran-
domized clinical trials.
The 3-year overall survival of 61.7 % in our patients
with gastrectomy and D2 lymphadenectomy alone (GL) is
a satisfactory outcome, although inferior to the finding of
the ACTS-GS Group trial in a patient population with D2
or D3 lymphadenectomy, which recorded a 3-year overall
survival rate of 70.1 % [15]. In the present study, the
classification of lymphadenectomy was done on the basis
of operative reports; however, there was a wide variation in
the number of dissected lymph nodes, with at least 12 in
both groups, which is low for D2 resection. This observa-
tion, coupled with the presence of a higher percentage of
locally advanced disease in the sample studied could
explain the 3-year overall survival difference observed
between the resection-alone arm of the ACTS-GC Group
trial [15] and the similar arm in the present study.
The survival outcome of our group submitted to adju-
vant therapy was 64.4 % and this also can be considered
satisfactory. In the INT 0116 and ACTS-GS Group trials,
the 3-year survival rates were 50 and 80.1 %, respectively
[5, 15]. The population investigated in the latter trial pre-
sented an earlier stage of disease, with 49.9 % of the
patients in stages III and IV with no distant metastases
compared with 77 % of the patients in these stages in the
present study.
In summary, chemoradiotherapy based on 5-fluorouracil
seems to be an effective adjuvant therapy in patients with
gastric and EGJ adenocarcinoma submitted to D2 lym-
phadenectomy, and it will probably continue to be used as
one of the options of adjuvant therapy. Through the lessons
learned from breast and colon cancers, in which benefits
derived from adjuvant therapy have been noted to differ
according to the presence of prognostic and predictive
factors, and in consideration of the findings of the ARTIST
[17] and ToGA [19] trials, maybe it would be interesting to
examine carefully the design of more personalized ran-
domized trials for adjuvant therapy in gastric cancer that
take into account tailored therapies.
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